Experiences of injectable contraceptive users in an urban setting

Obstetrics and Gynecology

Volumn 88, Issue 2, 1996, Pages 227-233

  Sangi Haghpeykar, Haleh ^a   Poindexter III, Alfred N ^a   Bateman, Louise ^a   Ditmore, J Randall ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE;

ABDOMINAL CRAMP; ACNE; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRACEPTION; DEPRESSION; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; SKIN DISEASE; TREATMENT FAILURE; UNITED STATES; URBAN POPULATION;

EID: 0030222013     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(96)00194-9     Document Type: Article

References (21)

1. 1. Salem HT, Salah M, Aly MY, Thabet AI, Shaaban MM, Fathalla MF. Acceptability of injectable contraceptives in Assiut, Egypt. Contraception 1988;38:697-710.
2. 2. Gray RH, Parker RA, Diethelm P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. Br J Obstet Gynaecol 1981;88:317-21.
3. 3. WHO Special Programme of Research, Development, and Research Training in Human Reproduction; Task Force on Long-Acting Agents for the Regulation of Fertility. Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception 1983;28:1-20.
4. 4. Fraser IS, Dennerstein GJ. Depo-Provera use in an Australian metropolitan practice. Med J Aust 1994;160:553-6.
5. 5. Jarman H, Kovacs GT, Westcott M. Depo-Provera: A profile of current users. Aust N Z J Obstet Gynaecol 1990;30:74-6.
6. 6. WHO Special Programme of Research, Development, and Research Training in Human Reproduction; Task Force on Long-Acting Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone enanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects. Contraception 1978;17:395-406.
7. 7. WHO Special Programme of Research, Development, and Research Training in Human Reproduction; Task Force on Long-Acting Agents for the Regulation of Fertility. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg. II. The comparison of bleeding patterns. Contraception 1987;35:591-610.
8. 8. Schwallie PC, Assenzo R. Contraceptive use - Efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-9.
9. 9. WHO Special Programme of Research, Development, and Research Training in Human Reproduction; Task Force on Long-Acting Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate. 1. Use effectiveness. Contraception 1977;15: 513-33.
10. 10. Sangi-Haghpeykar H, Poindexter AN, Moseley DC, Bateman L, Reid ED. Characteristics of injectable contraceptive users in a low-income population in Texas. Fam Plann Perspect 1995;27:208-11.
11. 11. Frank ML, Poindexter AN, Cornin LM, Cox A, Bateman L. One-year experience with subdermal contraceptive implants in the United States. Contraception 1993;48:229-43.
12. 12. Cullins VE, Blumenthal PD, Remsburg RE, Huggins GR. Preliminary experience with Norplant in an inner-city population. Contraception 1993;47:193-203.
13. 13. Darney PD, Atkinson E, Tanner S, MacPherson S, Hellerstein S, Alvarado A. Acceptance and perceptions of Norplant among users in San Francisco, USA. Stud Fam Plann 1990;21:152-60.
14. 14. Sivin I, Sanchez FA, Diaz S, Holma P, Coutinho E, McDonald O, et al. Three year experience with Norplant subdermal contraception. Fertil Steril 1983;39:799-808.
15. 15. Silverman J, Torres A, Forrest JD. Barriers to contraceptive services. Fam Plann Perspect 1987;19:94-102.
16. 16. Forrest JD. Epidemiology of unintended pregnancy and contraceptive use. Am J Obstet Gynecol 1994;170:1485-9.
17. 17. Williams LB. Determinants of unintended childbearing among ever-married women in the United States: 1973-1988. Fam Plann Perspect 1991;22:212-21.
18. 18. Harlap D, Kost K, Forrest JD. Preventing pregnancy, protecting health: A new look at birth control in the United States. New York: The Allen Guttmacher Institute, 1991.
19. 19. Sobal J, Stunkard AJ. Socioeconomic status and obesity: A review of the literature. Psychol Bull 1989;105:260-75.
20. 20. Fakeye O. Contraception with subdermal levonorgestrel implants as an alternative to surgical contraception at Ilorin, Nigeria. Int J Gynaecol Obstet 1991;35:331-6.
21. 21. Grady WR, Hayward MD, Billy JO, Florey FA. Contraceptive switching among currently married women in the United States. J Biosoc Sci 1989;11:117-32.